» Articles » PMID: 33921394

The Clone Wars: Diagnosing and Treating Dysproteinemic Kidney Disease in the Modern Era

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Apr 30
PMID 33921394
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Dysproteinemic kidney diseases are disorders that occur as the result of lymphoproliferative (B cell or plasma cell) disorders that cause kidney damage via production of nephrotoxic monoclonal immunoglobulins or their components. These monoclonal immunoglobulins have individual physiochemical characteristics that confer specific nephrotoxic properties. There has been increased recognition and revised characterization of these disorders in the last decade, and in some cases, there have been substantial advances in disease understanding and treatments, which has translated to improved patient outcomes. These disorders still present challenges to nephrologists and patients, since they are rare, and the field of hematology is rapidly changing with the introduction of novel testing and treatment strategies. In this review, we will discuss the clinical presentation, kidney biopsy features, hematologic characteristics and treatment of dysproteinemic kidney diseases.

Citing Articles

A Diverse Spectrum of Immune Complex- and Complement-Mediated Kidney Diseases Is Associated With Mantle Cell Lymphoma.

Andeen N, Abdulameer S, Charu V, Zuckerman J, Troxell M, Kambham N Kidney Int Rep. 2022; 7(3):568-579.

PMID: 35257069 PMC: 8897291. DOI: 10.1016/j.ekir.2021.12.020.

References
1.
Clark W, Stewart A, Rock G, Sternbach M, Sutton D, Barrett B . Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143(11):777-84. DOI: 10.7326/0003-4819-143-11-200512060-00005. View

2.
Gumber R, Cohen J, Palmer M, Kobrin S, Vogl D, Wasserstein A . A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int. 2018; 94(1):199-205. DOI: 10.1016/j.kint.2018.02.020. View

3.
Sanchorawala V . Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2007; 1(6):1331-41. DOI: 10.2215/CJN.02740806. View

4.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun R, Klingel R, Meyer E . Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34(3):171-354. DOI: 10.1002/jca.21705. View

5.
Nasr S, Markowitz G, Stokes M, Seshan S, Valderrama E, Appel G . Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 2003; 65(1):85-96. DOI: 10.1111/j.1523-1755.2004.00365.x. View